Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label randomized and exploratory cohort study of SHR-8068 plus adebrelimab, bevacizumab, and platinum-based chemotherapy as first-line treatment for advanced biliary tract cancer
CTR20242183Phase 2Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CS1002 in biliary adenocarcinoma, sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Jul 2024; status: active.
02
Drugs
CS1002
03
Conditions
biliary adenocarcinoma
Beyond the preview
Go deeper on CTR20242183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242183.